

Date: August 23, 2017

|                                                                                                                                                                                                              |                                                                                                                                                                                                          |
|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| To<br><br>Listing Department,<br><b>NATIONAL STOCK EXCHANGE OF INDIA LIMITED</b><br>Exchange Plaza,<br>Bandra Kurla Complex, Bandra (E),<br><b>MUMBAI -400 051</b><br><br><b>Company Code No. AUROPHARMA</b> | To<br><br>The Corporate Relations Department<br><b>BSE LIMITED</b><br>Phiroz Jeejeebhoy Towers,<br>25 <sup>th</sup> floor, Dalal Street,<br><b>MUMBAI -400 001</b><br><br><b>Company Code No. 524804</b> |
|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

Dear Sirs,

**Sub: Transcript of earnings call.**

Please refer to our letter dated 5<sup>th</sup> August 2017 wherein we have intimated the schedule of Investors/Analysts call on 10<sup>th</sup> August 2017. In this connection, we would like to inform you that the Transcript of the Q1 FY 2017-18 earnings conference call of 10<sup>th</sup> August, 2017 has been uploaded on the website of the Company and is available in the following web link:

<http://www.aurobindo.com/docs/financial-results/2017-2018/aurobindo-pharma-q1-fy-18-earnings-call-transcript.pdf>

Please take the information on record.

Thanking you,

Yours faithfully,  
**For AUROBINDO PHARMA LIMITED**

  
**B. Adi Reddy**  
Company Secretary

